Polycythemia vera in young patients: A study on the long-term risk of thrombosis, myelofibrosis and leukemia

Haematologica

Volumn 88, Issue 1, 2003, Pages 13-18

  Passamonti, Francesco ^a   Malabarba, Lucia ^b   Orlandi, Ester ^b   Baraté, Claudia ^b   Canevari, Angelo ^b   Brusamolino, Ercole ^b   Bonfichi, Maurizio ^b   Arcaini, Luca ^b   Caberlon, Sabrina ^b   Zappasodi, Patrizia ^b   Pascutto, Cristiana ^b   Lazzarino, Mario ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b NONE

Author keywords

Chronic myeloproliferative disorders; Polycythemia vera; Second malignancies; Thrombosis; Young patients

Indexed keywords

HEPARIN; HYDROXYUREA; PIPOBROMAN;

ADULT; AGE; ARTICLE; CALCULATION; COHORT ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; GENDER; HUMAN; ITALY; KAPLAN MEIER METHOD; LEUKEMIA; LIFE EXPECTANCY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOFIBROSIS; MYELOID METAPLASIA; PHLEBOTOMY; POLYCYTHEMIA VERA; RETROSPECTIVE STUDY; RISK; SECOND CANCER; SURVIVAL; THROMBOSIS; TREATMENT OUTCOME; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGE FACTORS; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LEUKEMIA; LONGITUDINAL STUDIES; MALE; MYELOFIBROSIS; POLYCYTHEMIA VERA; RISK FACTORS; SURVIVAL ANALYSIS; THROMBOSIS; TREATMENT OUTCOME;

EID: 0037309554     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Fernandez-Luna JL, Silva M, Richard C, Sanz C, Benito A. Pathogenesis of polycythemia vera. Haematologica 1998;83:150-8.
2. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995;123:656-64.
3. Leone G, Sica S, Chiusolo P, Teofili L, De Stefano V. Blood cells diseases and thrombosis. Haematologica 2001;86:1236-44.
4. Tefferi A. Current management of polycythemia vera. Leuk Lymphoma 2002;43:1-7.
5. Spivak JL. The optimal management of polycythaemia vera. Br J Haematol 2002;116:243-54.
6. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978;2:1219-22.
7. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986;23:132-43.
8. Barbui T, Finazzi G. Treatment of polycythemia vera. Haematologica 1998;83:143-9.
9. Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997;90:3370-7.
10. Passamonti F, Brusamolino E, Lazzarino M, Barate C, Klersy C, Orlandi E, et al. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica 2000;85:1011-8.
11. Messinezy M, Pearson TC, Prochazka A, Wetherley-Mein G. Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre. Br J Haematol 1985;61:657-66.
12. Najean Y, Mugnier P, Dresch C, Rain JD. Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years. Br J Haematol 1987;67:285-91.
13. Frezzato M, Ruggeri M, Castaman G, Rodeghiero F. Polycythemia vera and essential thrombocythemia in young patients. Haematologica 1993;78 Suppl 2:11-7.
14. Perea G, Remacha A, Besses C, Jimenez M, Florensa L, Cervantes F. Is polycythemia vera a serious disease in young adults? Haematologica 2001;86:543-4.
15. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975;12:339-51.
16. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103:620-5.
17. Passamonti F, Malabarba L, Orlandi E, Pascutto C, Brusamolino E, Astofi C, et al. Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. Br J Haematol 2002;116:855-61.
18. Barbui T, Finazzi G. Risk factors and prevention of vascular complications in polycythemia vera. Semin Thromb Hemost 1997;23:455-61.
19. Landolfi R, Marchioli R. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial. Semin Thromb Hemost 1997;23:473-8.
20. Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91:616-22.
21. Merlat A, Lai JL, Sterkers Y, Demory JL, Bauters F, Preudhomme C, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia 1999;13:250-7.
22. Berk PD, Goldberg JD, Silverstein MN, Weinfeld A, Donovan PB, Ellis JT, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981;304:441-7.
23. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997;34:17-23.
24. Finazzi G, Marchioli R, Barbui T. Life-expectancy of causes of death in 252 patients with polycythemia vera below 50 years of age. Blood 2000;96:741 [abstract].
25. Landaw SA. Acute leukemia in polycythemia vera. Semin Hematol 1986;23:156-65.
26. Anderson JE, Tefferi A, Craig F, Holmberg L, Chauncey T, Appelbaum FR, et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood 2001;98:586-93.
27. Jurado M, Deeg H, Gooley T, Anasetti C, Chauncey T, Flowers M, et al. Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia. Br J Haematol 2001;112:392-6.